Literature DB >> 991828

Dopamine/neuroleptic receptors in basal hypothalamus and pituitary.

G M Brown, P Seeman, T Lee.   

Abstract

In order to determine whether the basal hypothalamus or the pituitary (or both) is the likely locus of action of the tuberoinfundibular (TI) dopamine neurons, these regions were examined for dopamine and neuroleptic receptors. High affinity receptors for haloperidol and dopamine were found in the rat pituitary while none were detected in rat basal hypothalamus. The relative ability of two neuroleptics, chlorpromazine and haloperidol, to displace (3H)haloperidol from the receptor in monkey pituitary is similar to that for rat striatum. The lack of receptors capable of binding (3H)haloperidol or (3H)dopamine in the basal hypothalamus strongly suggests that the TI neurons do not produce postsynaptic effects in this region. The pituitary receptors for (3H)haloperidol and (3H)dopamine have the characteristics of a functional system. The presence of neuroleptic/dopamine receptors in the pituitary and lack of such receptors in the basal hypothalamus supports the hypothesis that dopamine may act directly as a prolactin release inhibiting factor (PIF) rather than releasing PIF from adjacent nerve terminals in the median eminence.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 991828     DOI: 10.1210/endo-99-5-1407

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

Review 1.  Control of prolactin secretion by excitatory amino acids.

Authors:  György M Nagy; Ibolya Bodnár; Zsuzsanna Bánky; Béla Halász
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

Review 2.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

Review 3.  Ontogenic studies of the neural control of adenohypophyseal hormones in the rat. II. Prolactin.

Authors:  D Becú-Villalobos; I M Lacau-Mengido; G S Díaz-Torga; C Libertun
Journal:  Cell Mol Neurobiol       Date:  1992-02       Impact factor: 5.046

4.  Bromocriptine reduces rat thyrotropin beta-subunit mRNA stability.

Authors:  A Levy; S L Lightman
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

Review 5.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

6.  Ultrastructural changes in rat mammotropes following incubation with dopamine.

Authors:  M Joneja; C W Reifel; M L Murphy; S H Shin
Journal:  Experientia       Date:  1993-10-15

7.  Inhibition of thyrotropin and prolactin secretion by dopamine in man.

Authors:  F Massara; F Camanni; V Vergano; L Belforte; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

8.  A radioenzymatic method to measure picogram amounts of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) in small samples of brain tissue.

Authors:  A Argiolas; F Fadda
Journal:  Experientia       Date:  1978-06-15

9.  Effects of pimozide and bromocriptine on anterior pituitary cell proliferation.

Authors:  H Stepień; A Wolaniuk; M Pawlikowski
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

10.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.